CLINICAL TRIALS PROFILE FOR BASIMGLURANT
✉ Email this page to a colleague
Clinical Trials for Basimglurant
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02433093 ↗ | A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD) | Completed | Hoffmann-La Roche | Phase 1 | The study will assess the safety, tolerability, and pharmacokinetics of basimglurant compared to placebo after multiple ascending oral doses for up to 22 days in healthy subjects and in patients with MDD on stable selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) background therapy. |
| NCT05059327 ↗ | Basimglurant in Children and Adolescents With TSC | Not yet recruiting | Noema Pharma AG | Phase 2 | The study intends to show that basimglurant provides effective seizure control in children and adolescents with Tuberous Sclerosis Complex (TSC). |
| NCT05217628 ↗ | An Efficacy and Safety Study of Basimglurant in Patients With Trigeminal Neuralgia. | Recruiting | Noema Pharma AG | Phase 2/Phase 3 | Trigeminal neuralgia (TN), also called "tic douloureux", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice. This study is designed to evaluate the efficacy and safety of 1.5mg - 3.5mg basimglurant in adults with TN. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Basimglurant
Condition Name
Clinical Trial Locations for Basimglurant
Trials by Country
Clinical Trial Progress for Basimglurant
Clinical Trial Phase
Clinical Trial Sponsors for Basimglurant
Sponsor Name
